Study S001863

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

ClinicalTrials.gov record

Registration

Registration: NCT07037459
Acronym: MARITIME-HF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: RECRUITING
Enrollment: 5056
Start: 2025-06-25
Primary completion: 2028-06-30
Lead sponsor: Amgen
Conditions: Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity
Interventions: DRUG:Maridebart cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF Events [Up to approximately 35 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.